Fundraising Fox

Opus Genetics

NASDAQ: IRD

Raleigh, US · Founded 2021 · Delaware corporation · 2 known investors

opusgtx.com ↗

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing AAV-based gene therapies and a small-molecule therapy to treat inherited retinal diseases and other vision disorders. Its pipeline includes seven gene therapy assets and one FDA-approved product, targeting patients with severe retinal disorders and common vision conditions.

BiotechHealthtechMedical Devicesin /opus-genetics

Founders & leadership

BR
BENJAMIN R. YERXAExecutive Officer, Director
JB
JEAN BENNETTDirector
RK
RUSSELL KELLEYExecutive Officer, Director
GM
George MagrathChief Executive Officer
BY
Ben YerxaPresident
RG
Robert GagnonChief Financial Officer
JS
Joe SchachleChief Operating Officer
AJ
Ash JayagopalChief Scientific and Development Officer
ST
Sally TuckerChief Medical Officer
ST
Sarah TullerChief Regulatory Officer
CE
Chris ErnstChief Technology Officer

Investors · 2

Michigan Capital NetworkGrand Rapids
Oberland CapitalNew York · $50M – $300M

Reported raises · per SEC filings

Form D private placements
▶$4.5MraisedJun 2023 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • JEAN BENNETTDirector
  • RUSSELL KELLEYDirector
  • BENJAMIN R. YERXAExecutive Officer, Director
  • ADRIENNE GRAVESDirector
Offering amount
$20M
Amount sold
$4.5M
First sale
Jun 2023
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.5MraisedAug 2021 · 5 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • BENJAMIN R. YERXAExecutive Officer, Director
  • JEAN BENNETTDirector
  • RUSSELL KELLEYExecutive Officer, Director
Offering amount
$19M
Amount sold
$9.5M
First sale
Aug 2021
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.